Abrocitinib for Food Allergy

"Patients whose condition has been identified as requiring a therapeutic procedure, who have experienced the failure of one or more systemic therapies and are candidates for additional systemic therapy may be administered Abrocitinib 100mg."

"Pfizer's Abrocitinib 100mg drug is currently the subject of 2 active trials across 210 cities and 28 countries. The first study, launched in 2018 as part of Phase 3 for drug approval, enrolled over 3000 participants to evaluate its efficacy. Since then, 26 additional investigations have been conducted concerning this medication."

"Due to the limited clinical data available on Abrocitinib 100mg, our team at Power has assigned it a score of 1 in terms of safety. This is an initial Phase 1 trial and there are only preliminary findings regarding efficacy."

"The age restriction for eligibility in this trial is between 18 and 50 years old. By contrast, there are 86 studies available to those younger than 18, while 159 trials exist that seek patients 65 or older."

"At the moment, there is one Phase 3 study and another currently in progress for Abrocitinib 100mg. Most of these trials are situated near Saint Petersburg, Maryland but it can be found at 562 other locations across the world."

"This research study is currently enlisting 40 individuals with food allergies in the 18 - 50 age range. To be eligible, they must exhibit an history of allergic reactions to peanuts, cashew nuts, walnuts, hazelnuts, sesame seeds cod and/or shrimp; have a positive IgE skin or serum test result; practice avoidance of the allergenic foods; carry physician-prescribed epinephrine injectors at all times; possess eczema current or past; if female and of childbearing potential should provide proof that she isn't pregnant before enrolling and agree to abstinence from sexual activity during the trial period or use"

"Affirmative. According to the data hosted by clinicaltrials.gov, this research is currently in search of participants with its initial posting date on May 16th 2022 and latest edit occurring on July 29th 2022. This study requires 40 patients from a single site location."

"Affirmative. According to information listed on clinicaltrials.gov, this medical study has been available since May 16th 2022 and was last updated in July 29th 2022; seeking a total of 40 participants from 1 site."